Patient perspectives generate specific outcome objectives, what they are willing to do to achieve them, the risks they are willing to bear, and the costs they are willing to pay. The same could be said about payers.
Merck announced that they are stopping their head to head comparative phase 3 study in advanced melanoma early since they met their primary endpoint ahead of schedule. In the competitive world of big pharma, that is considered a slam dunk.
Rare Disease Community is a collaborative one between patients and industry. In this exclusive interview with Rare Disease Report, Kevin Lee, PhD, chief scientific officer of Pfizer's rare disease research unit discusses some of the programs Pfizer has established to help the drug developers learn what the patients want and need.
Two companies were recently given 10-year National Institute of Neurological Disorders and Stroke (NINDS) awards from the National Institutes of Health (NIH) to advance drug development and provide manufacturing services for potential treatments for neurological disorders.